The MarketWatch News Department was not involved in the creation of this content.-- Wegovy(R) (semaglutide injection) granted conditional marketing authorization for the treatment ...

Novo Nordisk announced today that Health Canada has issued marketing authorization with conditions [Notice of Compliance with ...

Learn about semaglutide’s effectiveness and clinical trial results and whether it could be right for you in your MASH ...

Medications like Ozempic mimic a naturally occurring hormone called glucagon-like peptide-1, or GLP-1, which helps regulate blood sugar and appetite. GLP-1 is primarily secreted from the intestines, ...

Can Novo Nordisk get its comeback going in 2026? Let's discuss two things that could materialize for the company next year ...

Every year in biopharma brings its share of grueling defeats, and 2025 was no different, especially for companies targeting ...

We knew that GLP-1 drugs like Ozempic and Wegovy did more than just help control type 2 diabetes and aid weight loss, but the ...

Groundbreaking Harvard research reveals gut-produced molecules significantly influence obesity and blood sugar control. These ...

Aviceda Therapeutics ("the Company" or "Aviceda"), a clinical-stage biotechnology company developing innovative therapies for retinal diseases, today announced topline results from its SIGLEC Phase 2b ...

PureHealth Research today announced the launch of its new line of vein health supplements, offering a natural approach to supporting healthy circulation and promoting the appearance of ...

Novo, however, vastly underestimated the appetite for its new weight-loss jab. Mr Doustdar says it planned for demand to be three times that of Saxenda, an older and less-effective weight-loss drug.

They improve insulin sensitivity, reduce hunger signals and help people feel fuller for longer. They don’t magically repair ...